Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tramontane Therapeutics
Barcelona, Catalonia, Spain
- Ownership
- Private
- Development stage
- Other
01
Overview
Tramontane Therapeutics’ lead AAV-FGF21 gene therapy program for nonalcoholic steatohepatitis (NASH) and obesity has generated strong, durable efficacy across multiple validated animal models, and is expected by acquirer Kriya Therapeutics to advance into first-in-human clinical trials around 2025; no human clinical data have been reported yet.[1][2][4][7][9]
- Therapeutic areas
- EndocrinologyNeurologyGastroenterologyMetabolic Disorders
- Modalities
- Gene therapyAdeno-associated virus (AAV) vector
- Industry
- Biotech
02
Partnerships
Kriya Therapeutics (acquirer and development/commercialization partner)
Beyond the preview
Go deeper on Tramontane Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tramontane Therapeutics.